Last reviewed · How we verify
BP-C1
At a glance
| Generic name | BP-C1 |
|---|---|
| Also known as | Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin, Cis-diammineplatinum(II) complexed with a polymer containing benzene polycarboxylic acids derived from lignin, Benzene polycarboxylic acids complex with cis-diammineplatinum(II), Cis-diammineplatinum(II) complex, containing mono-deprotonated benzene-poly-carboxylic acids, derived from lignin, and hydroxyl group as O-donor ligands |
| Sponsor | Meabco A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer (PHASE1)
- BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer (PHASE2)
- BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment (PHASE2)
- BP-C1 in Metastatic Breast Cancer Patients (PHASE1)
- BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer (PHASE2)
- BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |